Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

Indianapolis-based Lilly is testing its weight loss drug Zepbound to treat addiction, while Meta outages affected more than ...

Eli Lilly ( LLY -0.44%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...

People struggling with their body weight experienced joy when new, more effective prescription drug options became the rage ...

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...

Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...

With supply shortages fading and new indications growing, the main question for obesity drugmakers entering the new year is ...

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.

Joe Breen, 38, is one of thousands of people whose experiences with GLP-1s such as Ozempic and Wegovy have radically changed their relationship with alcohol. Are these drugs the future for treating ...